Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver; Gunjan L. Shah; Neha S. Korde; Lindsey E. Roeker; Anthony R. Mato; Connie L. Batlevi; David J. Chung; Sital Doddi; Lorenzo Falchi; Boglarka Gyurkocza; Audrey Hamilton; Ya Hui Lin; Ann A. Jakubowski; Erel Joffe; Heather L. Landau; Richard J. Lin; Sham Mailankody; M. Lia Palomba; Jae H. Park; Miguel Angel Perales; Doris M. Ponce; Lakshmi V. Ramanathan; Gilles A. Salles; Michael Scordo; Susan K. Seo; Urvi A. Shah; Eytan M. Stein; David Straus; Saad Z. Usmani; James W. Young; Andrew D. Zelenetz; Ariela Noy; Santosha A. Vardhana

doi:10.1016/j.ccell.2022.05.007

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, Sital Doddi, Lorenzo Falchi, Boglarka Gyurkocza, Audrey Hamilton, Ya Hui Lin, Ann A. Jakubowski, Erel Joffe, Heather L. Landau, Richard J. Lin, Sham Mailankody, M. Lia Palomba, Jae H. Park, Miguel Angel PeralesDoris M. Ponce, Lakshmi V. Ramanathan, Gilles A. Salles, Michael Scordo, Susan K. Seo, Urvi A. Shah, Eytan M. Stein, David Straus, Saad Z. Usmani, James W. Young, Andrew D. Zelenetz, Ariela Noy^*, Santosha A. Vardhana^*

^*Corresponding author for this work

Memorial Sloan-Kettering Cancer Center

Research output: Contribution to journal › Letter › peer-review

76 Scopus citations

Original language	English
Pages (from-to)	590-591
Number of pages	2
Journal	Cancer Cell
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2022.05.007
State	Published - 13 Jun 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2022.05.007

Cite this

Stuver, R., Shah, G. L., Korde, N. S., Roeker, L. E., Mato, A. R., Batlevi, C. L., Chung, D. J., Doddi, S., Falchi, L., Gyurkocza, B., Hamilton, A., Lin, Y. H., Jakubowski, A. A., Joffe, E., Landau, H. L., Lin, R. J., Mailankody, S., Palomba, M. L., Park, J. H., ... Vardhana, S. A. (2022). Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell, 40(6), 590-591. https://doi.org/10.1016/j.ccell.2022.05.007

@article{628b9dd27ddd4e558952618e82b41bec,

title = "Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies",

author = "Robert Stuver and Shah, {Gunjan L.} and Korde, {Neha S.} and Roeker, {Lindsey E.} and Mato, {Anthony R.} and Batlevi, {Connie L.} and Chung, {David J.} and Sital Doddi and Lorenzo Falchi and Boglarka Gyurkocza and Audrey Hamilton and Lin, {Ya Hui} and Jakubowski, {Ann A.} and Erel Joffe and Landau, {Heather L.} and Lin, {Richard J.} and Sham Mailankody and Palomba, {M. Lia} and Park, {Jae H.} and Perales, {Miguel Angel} and Ponce, {Doris M.} and Ramanathan, {Lakshmi V.} and Salles, {Gilles A.} and Michael Scordo and Seo, {Susan K.} and Shah, {Urvi A.} and Stein, {Eytan M.} and David Straus and Usmani, {Saad Z.} and Young, {James W.} and Zelenetz, {Andrew D.} and Ariela Noy and Vardhana, {Santosha A.}",

note = "Funding Information: The authors report no competing interests related to the research. S.A.V. is an advisor for Immunai and previously consulted for ADC Therapeutics and Koch Disruptive Technologies. A.N. is an advisor for Janssen, Morphosys, and Epizyme, has consulted for Physician Education Resource, has received honoraria from Medscape and Pharmacyclics, and has received research funding from Pharmacyclics and Rafael Pharmaceuticals . ",

year = "2022",

month = jun,

day = "13",

doi = "10.1016/j.ccell.2022.05.007",

language = "אנגלית",

volume = "40",

pages = "590--591",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

Stuver, R, Shah, GL, Korde, NS, Roeker, LE, Mato, AR, Batlevi, CL, Chung, DJ, Doddi, S, Falchi, L, Gyurkocza, B, Hamilton, A, Lin, YH, Jakubowski, AA, Joffe, E, Landau, HL, Lin, RJ, Mailankody, S, Palomba, ML, Park, JH, Perales, MA, Ponce, DM, Ramanathan, LV, Salles, GA, Scordo, M, Seo, SK, Shah, UA, Stein, EM, Straus, D, Usmani, SZ, Young, JW, Zelenetz, AD, Noy, A & Vardhana, SA 2022, 'Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies', Cancer Cell, vol. 40, no. 6, pp. 590-591. https://doi.org/10.1016/j.ccell.2022.05.007

TY - JOUR

T1 - Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

AU - Stuver, Robert

AU - Shah, Gunjan L.

AU - Korde, Neha S.

AU - Roeker, Lindsey E.

AU - Mato, Anthony R.

AU - Batlevi, Connie L.

AU - Chung, David J.

AU - Doddi, Sital

AU - Falchi, Lorenzo

AU - Gyurkocza, Boglarka

AU - Hamilton, Audrey

AU - Lin, Ya Hui

AU - Jakubowski, Ann A.

AU - Joffe, Erel

AU - Landau, Heather L.

AU - Lin, Richard J.

AU - Mailankody, Sham

AU - Palomba, M. Lia

AU - Park, Jae H.

AU - Perales, Miguel Angel

AU - Ponce, Doris M.

AU - Ramanathan, Lakshmi V.

AU - Salles, Gilles A.

AU - Scordo, Michael

AU - Seo, Susan K.

AU - Shah, Urvi A.

AU - Stein, Eytan M.

AU - Straus, David

AU - Usmani, Saad Z.

AU - Young, James W.

AU - Zelenetz, Andrew D.

AU - Noy, Ariela

AU - Vardhana, Santosha A.

N1 - Funding Information: The authors report no competing interests related to the research. S.A.V. is an advisor for Immunai and previously consulted for ADC Therapeutics and Koch Disruptive Technologies. A.N. is an advisor for Janssen, Morphosys, and Epizyme, has consulted for Physician Education Resource, has received honoraria from Medscape and Pharmacyclics, and has received research funding from Pharmacyclics and Rafael Pharmaceuticals .

PY - 2022/6/13

Y1 - 2022/6/13

UR - http://www.scopus.com/inward/record.url?scp=85132188475&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.05.007

DO - 10.1016/j.ccell.2022.05.007

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35598602

AN - SCOPUS:85132188475

SN - 1535-6108

VL - 40

SP - 590

EP - 591

JO - Cancer Cell

JF - Cancer Cell

IS - 6

ER -

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

UN SDGs

Access to Document

Other files and links

Cite this